SCHEMBL3821569

SCHEMBL3821569

O=C(O)c1ccc2c(c1)CC[C@@H]1CN(Cc3ccccc3Br)CCN21

nearest known ligand 0.48

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 3/20 0.48
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3824832 0.86 DRD3 (0.52) DRD3
SCHEMBL3824836 0.86 DRD3 (0.52) DRD3
Hydrochloric Acid SCHEMBL5127297 0.86 DRD2 (0.48) DRD3
Hydrochloric Acid SCHEMBL5126425 0.86 DRD3 (0.46) DRD3
Hydrochloric Acid SCHEMBL5130057 0.86 DRD2 (0.48) DRD3
Hydrochloric Acid SCHEMBL5126419 0.86 DRD3 (0.46) DRD3
Hydrochloric Acid SCHEMBL5131654 0.85 DRD3 (0.46) DRD3
Hydrochloric Acid SCHEMBL5131655 0.85 DRD3 (0.46) DRD3
SCHEMBL3820897 0.85 DRD3 (0.46) DRD3
SCHEMBL5129234 0.83 DRD2 (0.45) DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1953161-B1 New tricyclic derivatives, method of preparing same and pharmaceutical compositions containing them SERVIER LAB (FR) 2009-08-26 EP disclosed
WO-2008110691-A1 NOVEL TRICYCLIC DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2008-09-18 WO disclosed
US-20080188460-A1 Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2008-08-07 US disclosed
EP-1953161-A1 New tricyclic derivatives, method of preparing same and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2008-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188460-A1 Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them BAX, BCL2, CASP3 DRD3 2499/4885KDM4E 3753/4885ALDH1A1 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.